GlassScriptPhysician profile
Onyedika John Ilonze
NPI 1174752554
$125,354.88
in general payments reported to CMS, 2019-2025
28 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $244 · 2021: $54.90 · 2022: $16K · 2023: $24K · 2024: $25K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $7,332 · Food and Beverage: $6,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,137.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,123.00 |
| Travel and Lodging | $7,332.49 |
| Food and Beverage | $6,308.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,508.66 | 2023-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $31,368.76 | 2022-2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $14,924.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $8,774.08 | 2022-2025 | Verquvo, Keytruda |
| Scpharmaceuticals INC. | $8,196.04 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $7,512.09 | 2019-2023 | |
| Bridgebio Pharma, INC. | $6,221.43 | 2025 | Attruby |
| Gilead Sciences, INC. | $2,681.87 | 2022-2024 | |
| Abbott Laboratories | $1,509.88 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $1,493.56 | 2019-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $627.67 | 2019-2025 | Amvuttra |
| Medtronic, INC. | $550.36 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $504.53 | 2019-2025 | Uptravi |
| Pfizer INC. | $355.61 | 2019-2025 | |
| United Therapeutics Corporation | $313.53 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $300.00 | 2022 | |
| Novo Nordisk INC | $133.84 | 2024-2025 | Ozempic |
| Amgen INC. | $102.67 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.85 | 2019-2023 | Lifevest |
| Baxter Healthcare | $44.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.11 | 2019 | |
| Akcea Therapeutics, INC. | $20.03 | 2019 | |
| Teleflex LLC | $19.30 | 2023 | Guideliner |
| Boston Scientific Corporation | $17.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.66 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $6.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onyedika Ilonze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.